GlobeNewswire Inc.24 ago 2026, 20:00
Belite Bio to Host Virtual Commercial Day on September 2, 2026
Belite Bio announced that the FDA accepted and granted Priority Review designation for its New Drug Application for tinlarebant to treat Stargardt disease type 1 (STGD1), with a decision date set for February 12, 2027. The company will host a Virtual Commercial Day on September 2, 2026, to discuss the drug's commercial opportunity and prelaunch preparedness strategies.
